A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

Andres Forero-Torres, John P. Leonard, Anas Younes, Joseph D. Rosenblatt, Pauline Brice, Nancy L. Bartlett, Andre Bosly, Lauren Pinter-Brown, Dana Kennedy, Eric L. Sievers, Ajay K. Gopal

Research output: Contribution to journalArticlepeer-review

219 Scopus citations


SGN-30, a chimeric anti-CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). We conducted an open-label, Phase II study to determine the safety and objective response rate of SGN-30 in 79 patients with refractory/recurrent HL (n = 38) or systemic ALCL (n = 41). Each course of SGN-30 comprised 6 weekly intravenous infusions, followed by a 2-week treatment-free period. Patients had received a median of 3 (range 1-5) prior regimens of chemotherapy or systemic therapy. The initial 40 patients received 6 mg/kg weekly; the latter 39 patients received 12 mg/kg weekly. In the ALCL group, two patients achieved a complete response and five additional patients achieved a partial response, with response durations ranging from 27 to 1460+ d. No objective responses were observed in the HL group; however, 11 patients (29%) had stable disease (duration 62-242 days). Although adverse events were common, most were mild or moderate, and no specific pattern of adverse events was observed in either disease group. These results demonstrate that weekly administration of SGN-30 is safe, with modest clinical activity in patients with ALCL.

Original languageEnglish
Pages (from-to)171-179
Number of pages9
JournalBritish Journal of Haematology
Issue number2
StatePublished - Jul 2009


  • Anaplastic large cell lymphoma
  • Anaplastic lymphoma kinase
  • Anti-CD30 antibody
  • Hodgkin lymphoma
  • Monoclonal antibody


Dive into the research topics of 'A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma'. Together they form a unique fingerprint.

Cite this